Allovir Inc at Morgan Stanley Global Healthcare Conference Transcript
All right. Good afternoon, everyone. Thanks for joining us at Morgan Stanley Global Healthcare Conference. I'm Mike Ulz, one of the biotech analysts here. It's my pleasure to introduce Diana Brainard, CEO of AlloVir.
Just a reminder, the format for today is a fireside chat. But before we get started, I just need to read a quick disclosure. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
And with that, Diana, thanks for joining us. And maybe I'll just turn it over to you for a brief introductory comments, and then we can get into Q&A.
Great. Sounds good. Thanks, Mike. Great to be here representing AlloVir. And this is a quick introduction. At AlloVir, we're a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |